Protalix BioTherapeutics Advances Rare Disease Treatments with PRX-115 and PRX-119 Innovations
- Protalix BioTherapeutics is advancing treatments for rare diseases with PRX-115 for uncontrolled gout and PRX-119 for kidney diseases.
- PRX-115 shows promising Phase 1 trial results, offering a rapid urate-lowering effect for gout patients.
- The company aims to capture 15-20% of the growing Fabry disease market with its successful Elfabrio® collaboration.
Protalix BioTherapeutics Advances Rare Disease Treatments with PRX-115 and PRX-119
Protalix BioTherapeutics, Inc., a biopharmaceutical company headquartered in Carmiel, Israel, is making significant strides in the treatment of rare diseases, particularly through its innovative pipeline that addresses unmet medical needs. The company's recent update, delivered by President and CEO Dror Bashan, emphasizes the promising Phase 1 trial results of PRX-115, a novel treatment for uncontrolled gout. This condition has seen a rising prevalence in the United States, underscoring the urgency for effective therapeutic options. PRX-115 showcases a rapid and durable urate-lowering effect, positioning it as a potential third commercialized molecule for Protalix and highlighting the company’s commitment to addressing high-demand conditions that impact patient quality of life.
In addition to tackling gout, Protalix is also focusing on rare kidney diseases with the development of PRX-119. This therapy aims to combat inflammation and fibrosis, common complications associated with such conditions. The increasing incidence of these diseases presents a critical opportunity for Protalix to deliver innovative treatments that can significantly improve patient outcomes. The company’s strategic approach not only focuses on developing these therapies but also aims to leverage partnerships and collaborations to enhance its market presence and ensure sustainable growth.
Protalix’s successful collaboration with Chiesi Global Rare Diseases, particularly in the launch of Elfabrio® for Fabry disease, further illustrates its commitment to providing valuable therapies. The growth in treated patient numbers and expanding market share in both the U.S. and Europe points to a strong commercial trajectory. As the global Fabry market is projected to reach approximately $3.4 billion by 2030, Protalix anticipates capturing 15% to 20% of this market, which would significantly bolster its position in the rare disease treatment landscape. The company is also actively reviewing the negative opinion from the European Medicines Agency received in November 2025, indicating a proactive approach to enhancing its market positioning.
In summary, Protalix BioTherapeutics is dedicated to advancing innovative solutions for rare diseases through its promising pipeline, strategic partnerships, and commitment to addressing unmet medical needs. With a strong focus on PRX-115 and PRX-119, the company aims to make impactful contributions to the treatment of gout and rare kidney diseases, while ensuring sustainable growth in a rapidly evolving biopharmaceutical landscape.